MannKind: fire at contract manufacturer delays MNKD-101 clinical supply by 3-6 months

MANNKIND CORP

Fire at contract manufacturer's German facility producing clofazimine inhalation solution (MNKD-101).
Production of clinical supplies delayed by 3-6 months.
Planned Phase 2/3 clinical study initiation for later 2023 may be impacted.
Company evaluating mitigation strategies; will update timing projections later.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.